Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
34
URGN Quote, Financials, Valuation and Earnings
Last price:
$23.46
Seasonality move
:
-2.48%
Day range:
$21.40 - $22.92
52-week range:
$3.42 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.26x
P/B ratio:
16.41x
Volume:
1.5M
Avg. volume:
1.2M
1-year change:
101.32%
Market cap:
$1.1B
Revenue:
$90.4M
EPS (TTM):
-$3.46
Analysts' Opinion
-
Consensus RatingUroGen Pharma Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.25, UroGen Pharma Ltd. has an estimated upside of 54.27% from its current price of $22.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $22.85.
Fair Value
-
According to the consensus of 7 analysts, UroGen Pharma Ltd. has 54.27% upside to fair value with a price target of $35.25 per share.
URGN vs. S&P 500
-
Over the past 5 trading days, UroGen Pharma Ltd. has overperformed the S&P 500 by 0.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
UroGen Pharma Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UroGen Pharma Ltd. has grown year-over-year revenues for 18 quarters straight. In the most recent quarter UroGen Pharma Ltd. reported revenues of $27.5M.
Earnings Growth
-
UroGen Pharma Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter UroGen Pharma Ltd. reported earnings per share of -$0.69.
Enterprise value:
1.1B
EV / Invested capital:
73.71x
Price / LTM sales:
11.26x
EV / EBIT:
--
EV / Revenue:
11.10x
PEG ratio (5yr expected):
-0.65x
EV / Free cash flow:
-7.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$84.9M
Return On Assets:
-66.98%
Net Income Margin (TTM):
-170.59%
Return On Equity:
--
Return On Invested Capital:
-209.52%
Operating Margin:
-99.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $77.3M | $89.4M | $96.5M | $25.2M | $27.5M | |
| Gross Profit | $67.9M | $80.7M | $84.9M | $22.8M | $24.2M | |
| Operating Income | -$71.2M | -$83.7M | -$133.4M | -$17.5M | -$27.4M | |
| EBITDA | -$69.5M | -$82.4M | -$131.4M | -$17.3M | -$26.7M | |
| Diluted EPS | -$4.23 | -$3.14 | -$3.46 | -$0.55 | -$0.69 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $125.1M | $121.6M | $182.1M | $295.1M | $168.5M | |
| Total Assets | $134.6M | $128.5M | $193.6M | $301.9M | $185M | |
| Current Liabilities | $19.8M | $19M | $25.8M | $32.8M | $42.2M | |
| Total Liabilities | $103.1M | $191.8M | $235.6M | $276.4M | $300.5M | |
| Total Equity | $31.5M | -$63.3M | -$42M | $25.5M | -$115.4M | |
| Total Debt | $616K | $73.7M | $99.5M | $121.9M | $129.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$81.9M | -$95.1M | -$143.7M | -$27.8M | -$47.5M | |
| Cash From Investing | $32.5M | -$91.9M | $95.7M | -$106.2M | $32.9M | |
| Cash From Financing | $137.1M | $193.4M | $9.8M | $40.1M | $8.7M | |
| Free Cash Flow | -$82M | -$95.4M | -$144.1M | -$27.9M | -$47.6M | |
URGN
Sector
Market Cap
$1.1B
$28M
Price % of 52-Week High
76.17%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-1.7%
-1.4%
1-Year Price Total Return
101.32%
-19%
Beta (5-Year)
1.214
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.78
200-day SMA
Buy
Level
$15.54
Bollinger Bands (100)
Buy
Level
17.37 - 23.25
Chaikin Money Flow
Buy
Level
38.2M
20-day SMA
Sell
Level
$24.78
Relative Strength Index (RSI14)
Sell
Level
47.07
ADX Line
Sell
Level
24.57
Williams %R
Buy
Level
-83.1395
50-day SMA
Buy
Level
$21.63
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
63.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8689)
Sell
CA Score
(Annual)
Level (-5.2211)
Buy
Beneish M-Score
(Annual)
Level (-2.7216)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.1921)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Stock Forecast FAQ
In the current month, URGN has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The URGN average analyst price target in the past 3 months is $35.25.
-
Where Will UroGen Pharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that UroGen Pharma Ltd. share price will rise to $35.25 per share over the next 12 months.
-
What Do Analysts Say About UroGen Pharma Ltd.?
Analysts are divided on their view about UroGen Pharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UroGen Pharma Ltd. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is UroGen Pharma Ltd.'s Price Target?
The price target for UroGen Pharma Ltd. over the next 1-year time period is forecast to be $35.25 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is URGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UroGen Pharma Ltd. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of URGN?
You can purchase shares of UroGen Pharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UroGen Pharma Ltd. shares.
-
What Is The UroGen Pharma Ltd. Share Price Today?
UroGen Pharma Ltd. was last trading at $23.46 per share. This represents the most recent stock quote for UroGen Pharma Ltd.. Yesterday, UroGen Pharma Ltd. closed at $22.85 per share.
-
How To Buy UroGen Pharma Ltd. Stock Online?
In order to purchase UroGen Pharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get URGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
URGN
Sector
P/E ratio
--
24.31x
PEG ratio
-0.65x
-0.01x
P/B ratio
16.41x
1.83x
Price / LTM sales
11.26x
1.60x
Growth Metrics
URGN
Sector
Revenue growth
9.04%
4.6%
Earnings growth
-26.35%
10.88%
Revenue (5-year growth)
449.77%
6.5%
Earnings forecast
-$0.68
-$0.20
Profitability
URGN
Sector
Profitability FY 2024
$81.5M
$3.5M
Return on invested capital
-209.52%
-31.66%
Return on assets
-66.98%
-27.84%
Return on equity
--
-37.28%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
5
Balance Sheet
URGN
Sector
Total cash
$128.4M
$26.8M
Short term investments
$64.7M
$26M
Total assets
$285.7M
$78.7M
Long term debt
$129.5M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
